EN DE
Watch Nosa Med AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nosa Med AB (NOSA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Nosa Med AB stock SEK 0.35, price SEK 0.44, that is 20.0% below the price, quality 25 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0006994539

NM Nosa Med AB logo Thin data Nov 10, 2026

Nosa Med AB

NOSA · ST
Expensive, weak quality

Our calculation puts a fair price 20% below what the stock costs today.

Low debt
Revenue last quarter +82% vs. a year ago.
Expensive Growth (revenue 5y +77.2 %/yr in SEK)
Fair value kr 0.3488 · Overvalued
Quality 25/100
Loss-making · -24.5% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Nosa Med AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 3.99 kr 0.2600 Fair Value kr 0.3488 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.2600 – kr 3.99 · fair‑value band kr 0.2616 – kr 0.4361 · the kr 0.4360 price screens above the kr 0.3488 fair value. As of Nov 10, 2026.

Follow Nosa Med in your weekly email

Every Wednesday you see whether Nosa Med is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nosa Plugs AB, a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, Europe, North America, Oceania, and internationally.

Show moreShow less

It offers NOSA smell training, a smell training medical device to improve the sense of smell for individuals with parosmia and hyposmia; NOSA odor control, which reduces bad odor; NOSA microbial control that reduces the exposure of viruses and bacteria by inhalation through the nose; NOSA Nozoil original, a moisturizing nasal spray for people suffering from dry nasal mucosa; and NOSA Cerevia, a nasal drug delivery platform for controlled administration of drugs.

The company was incorporated in 2014 and is headquartered in Stockholm, Sweden.

Stock analysis

Nosa Med AB (NOSA) currently trades at kr 0.4360, while our estimate is kr 0.3488, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.2616 (bear) to kr 0.4361 (bull), the price of kr 0.4360 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Nosa Med AB reported revenue of 23.9M SEK in FY2025 versus 5.9M SEK in FY2021, a compound +42.2%/yr. Reported net income was −8.0M SEK in FY2025.

Key figures

Market cap 113M SEK (≈ $11.5M) Micro · P/S ratio 3.46 · EPS (TTM) kr −0.0300 · Net margin −24.5% · Return on equity −18.6% · Return on assets (EBIT) −56.5% (5-year average) · Operating margin −22.5% · Revenue (TTM) 31.8M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −20%, NOSA screens richer than that median.

Fair Value

Bear kr 0.2616 Fair Value kr 0.3488 Bull kr 0.4361
Price kr 0.4360 · Downside -20.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+48.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+77.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+77.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7,596.2% (2020) → −33.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NOSA screens overvalued: fair value 20% below the price. Compare with Abbott Laboratories, →

Compare Nosa Med AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −20.0% · Below median
Profitability
Return on assets −12.4% · Below median
Net margin (12 months) −24.5% · Bottom 25%
Operating margin (12 months) −22.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 81.5% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.76× · Pricier than median
P/S (12 months) 3.56× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs NOSA
DexCom, Inc DXCM $79.92 $89.18 +12% vs NOSA
Stryker Corporation SYK $324.29 $358.30 +10% vs NOSA
STERIS plc STE $257.12 $279.53 +9% vs NOSA
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs NOSA
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs NOSA
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs NOSA
Abbott Laboratories, ABT $110.46 $75.28 −32% vs NOSA
Medtronic plc MDT $101.59 $65.61 −35% vs NOSA
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs NOSA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nosa Med AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nosa Med AB Fair Value". https://www.fairvalue-calculator.com/stock/NOSA

Frequently asked questions

Is Nosa Med AB (NOSA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.3488 versus a price of kr 0.4360, about 20% lower (overvalued).
What is the fair value of NOSA?
Our estimate for Nosa Med AB is kr 0.3488 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.4360.
What is the quality score of NOSA?
Nosa Med AB has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nosa Med AB (NOSA)?
Our calculated price target is the estimate of kr 0.3488 (as of Nov 10, 2026). Cautious scenario kr 0.2616, optimistic scenario kr 0.4361. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Nosa Med AB stock forecast for 2026?
Our estimate puts fair value at kr 0.3488, about 20% lower versus a price of kr 0.4360 (overvalued). Cautious scenario kr 0.2616, optimistic scenario kr 0.4361. The calculation is refreshed regularly with new filings.
What is the revenue of Nosa Med AB (NOSA)?
Nosa Med AB reported trailing-twelve-month revenue of about 31.8M SEK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Nosa Med AB (NOSA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nosa Med AB it is kr 0.3488 per share (as of Nov 10, 2026), against a price of kr 0.4360.
Is Nosa Med AB stock overvalued or undervalued in 2026?
As of Nov 10, 2026, NOSA trades above its calculated fair value: price kr 0.4360, fair value kr 0.3488, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NOSA?
No. The price is what the market pays today (kr 0.4360); the fair value is what the company's own numbers justify (kr 0.3488). For Nosa Med AB the two are kr 0.0872 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nosa Med AB worth?
The market values Nosa Med AB at about 113M SEK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.4360; our models calculate a fair value of kr 0.3488 per share.
What do the bullish and bearish scenarios say about NOSA?
Our models span a range for Nosa Med AB: cautious scenario kr 0.2616, base kr 0.3488, optimistic kr 0.4361 per share (as of Nov 10, 2026, price kr 0.4360). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nosa Med AB (NOSA)?
Balance-sheet figures for Nosa Med AB (as of Nov 10, 2026): return on equity −18.6%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is NOSA from its 52-week high?
Nosa Med AB trades at kr 0.4360, about 37% below its 52-week high of kr 0.6900 and 21% above the low of kr 0.3595 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.3488 is for.
Which stocks are comparable to Nosa Med AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nosa Med AB stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.4360, calculated fair value kr 0.3488 (−20%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Nosa Med AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nosa Med AB (NOSA)?
The closing price on Nov 10, 2026 was kr 0.4360. Our estimate is kr 0.3488, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nosa Med AB right now?
Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Nosa Med AB

How large is the market capitalisation of Nosa Med AB (NOSA)?
The market capitalisation of Nosa Med AB is 113M SEK (≈ $11.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nosa Med AB (NOSA)?
The price-to-sales ratio of Nosa Med AB is 3.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nosa Med AB (NOSA)?
Earnings per share at Nosa Med AB are kr −0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nosa Med AB (NOSA)?
The net margin of Nosa Med AB is −24.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nosa Med AB (NOSA)?
The return on equity (ROE) of Nosa Med AB is −18.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nosa Med AB (NOSA)?
On an EBIT basis the return on assets of Nosa Med AB is −56.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nosa Med AB (NOSA)?
The operating margin of Nosa Med AB is −22.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nosa Med AB (NOSA)?
Revenue at Nosa Med AB is growing +81.5% versus a year earlier (3y avg +51.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nosa Med AB (NOSA) generate?
The free cash flow of Nosa Med AB is −6.4M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nosa Med AB (NOSA) hold?
Nosa Med AB holds more cash than debt, 16.6M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Nosa Med AB in the live analysis

One click puts Nosa Med AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.